JP2017500295A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017500295A5 JP2017500295A5 JP2016533648A JP2016533648A JP2017500295A5 JP 2017500295 A5 JP2017500295 A5 JP 2017500295A5 JP 2016533648 A JP2016533648 A JP 2016533648A JP 2016533648 A JP2016533648 A JP 2016533648A JP 2017500295 A5 JP2017500295 A5 JP 2017500295A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- pharmaceutically acceptable
- acceptable salt
- tautomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 27
- 239000001257 hydrogen Substances 0.000 claims 27
- 229910052739 hydrogen Inorganic materials 0.000 claims 27
- 150000003839 salts Chemical class 0.000 claims 27
- 239000012453 solvate Substances 0.000 claims 25
- 150000002431 hydrogen Chemical class 0.000 claims 21
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 14
- 125000002252 acyl group Chemical group 0.000 claims 11
- 208000024412 Friedreich ataxia Diseases 0.000 claims 6
- 208000018565 Hemochromatosis Diseases 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 6
- 206010065973 Iron Overload Diseases 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- 230000001575 pathological effect Effects 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 206010072735 Aluminium overload Diseases 0.000 claims 3
- 208000018652 Closed Head injury Diseases 0.000 claims 3
- 208000035473 Communicable disease Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000012902 Nervous system disease Diseases 0.000 claims 3
- 208000025966 Neurological disease Diseases 0.000 claims 3
- 206010063837 Reperfusion injury Diseases 0.000 claims 3
- 208000002903 Thalassemia Diseases 0.000 claims 3
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 3
- 229910052768 actinide Inorganic materials 0.000 claims 3
- 150000001255 actinides Chemical class 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 206010012601 diabetes mellitus Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000019622 heart disease Diseases 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 3
- 229910052747 lanthanoid Inorganic materials 0.000 claims 3
- 150000002602 lanthanoids Chemical class 0.000 claims 3
- 208000019423 liver disease Diseases 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 230000000926 neurological effect Effects 0.000 claims 3
- 230000036542 oxidative stress Effects 0.000 claims 3
- 230000005855 radiation Effects 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 150000004677 hydrates Chemical class 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 239000011593 sulfur Substances 0.000 claims 2
- 125000004434 sulfur atom Chemical group 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361907913P | 2013-11-22 | 2013-11-22 | |
| US61/907,913 | 2013-11-22 | ||
| PCT/US2014/066965 WO2015077655A1 (en) | 2013-11-22 | 2014-11-21 | Desferrithiocin analogs and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017500295A JP2017500295A (ja) | 2017-01-05 |
| JP2017500295A5 true JP2017500295A5 (enExample) | 2018-08-16 |
| JP6838966B2 JP6838966B2 (ja) | 2021-03-03 |
Family
ID=53180232
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016533648A Expired - Fee Related JP6838966B2 (ja) | 2013-11-22 | 2014-11-21 | デスフェリチオシン類似体およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10010535B2 (enExample) |
| EP (1) | EP3071201A4 (enExample) |
| JP (1) | JP6838966B2 (enExample) |
| AU (1) | AU2014352780A1 (enExample) |
| CA (1) | CA2930966A1 (enExample) |
| WO (1) | WO2015077655A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0610644B8 (pt) | 2005-04-04 | 2021-05-25 | Univ Florida | composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável. |
| KR102111176B1 (ko) | 2011-12-16 | 2020-05-15 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 4'-데스페리티오신 유사체의 용도 |
| JP2018515475A (ja) | 2015-04-27 | 2018-06-14 | ユニバーシティー オブ フロリダ リサーチ ファンデーション， インク． | 代謝的にプログラムされた金属キレーターおよびその使用 |
| CO2018004165A2 (es) | 2015-10-23 | 2018-09-20 | Vifor Int Ag | Inhibidores de ferroportina |
| EA039916B1 (ru) * | 2015-10-23 | 2022-03-28 | Вифор (Интернациональ) Аг | Новые ингибиторы ферропортина |
| US10982136B2 (en) | 2016-02-26 | 2021-04-20 | The Regents Of The University Of California | Ligand-sensitized lanthanide nanocrystals as ultraviolet downconverters |
| EP3503930B1 (en) | 2016-08-29 | 2024-12-11 | Fred Hutchinson Cancer Center | Chelating platform for delivery of radionuclides |
| CA3035966A1 (en) | 2016-09-06 | 2018-03-15 | The Regents Of The University Of California | Formulations of hydroxypyridonate actinide/lanthanide decorporation agents |
| EP3520117B1 (en) | 2016-09-29 | 2023-11-08 | The Regents of The University of California | Separation of metal ions by liquid-liquid extraction |
| CA3038670A1 (en) | 2016-09-29 | 2018-04-05 | The Regents Of The University Of California | Chelating molecules |
| JOP20180036A1 (ar) | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
| TW202102478A (zh) | 2019-04-01 | 2021-01-16 | 瑞士商威佛（國際）股份有限公司 | 新穎的鐵螯合物 |
| US20220273634A1 (en) * | 2019-07-19 | 2022-09-01 | Vifor (International) Ag | Ferroportin-Inhibitors For The Use In The Treatment Of Transfusion-Dependent Beta-Thalassemia (TDT) |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3274207A (en) | 1966-09-20 | Processes for preparing thiazole carboxylic acids | ||
| US3809754A (en) | 1968-12-31 | 1974-05-07 | Medial De Toledo & Cie | Method of treating diseases of the mucous membrane using compounds of a thiazolidine carboxylic acid and pharmaceutical preparations thereof |
| US3882110A (en) | 1969-06-11 | 1975-05-06 | Roussel Uclaf | Novel 2-alkyl-5-thiazole-carboxylic acid derivatives |
| FR2062210A5 (enExample) | 1969-09-17 | 1971-06-25 | Godo Shusei Kk | |
| FR2141526B1 (enExample) | 1971-06-14 | 1975-05-30 | Roussel Uclaf | |
| DE2245560A1 (de) | 1972-09-16 | 1974-03-21 | Basf Ag | Verfahren zur herstellung von 4alkoxycarbonyl-2-thiazolinen |
| US4430344A (en) | 1978-04-08 | 1984-02-07 | Santen Pharmaceutical Co., Ltd. | Antihypertensive 4-thiazolidinecarboxylic acids |
| DE3002989A1 (de) | 1980-01-29 | 1981-07-30 | Hoechst Ag, 6000 Frankfurt | Hydroxyphenyl-thiazol, -thiazolin und -thiazolidin-carbonsaeuren, verfahren zu ihrer herstellung und ihre verwendung zur beeinflussung des kollagenstoffwechsels |
| JPS5758682A (en) | 1980-07-28 | 1982-04-08 | Ciba Geigy Ag | Thiazoline derivatives, manufacture and medicinal composition containing same |
| EP0045281B1 (de) | 1980-07-28 | 1985-05-08 | Ciba-Geigy Ag | Thiazolinderivate und Verfahren zu ihrer Herstellung |
| JPS5772975A (en) | 1980-10-24 | 1982-05-07 | Kureha Chem Ind Co Ltd | 2-substituted phenylthiazole derviative, and medicine for peptic ulcer containing said derivative as active component |
| US4367233A (en) | 1981-10-02 | 1983-01-04 | American Home Products Corporation | Inhibitors of mammalian collagenase |
| HU200177B (en) | 1985-06-18 | 1990-04-28 | Biogal Gyogyszergyar | Process for producing thiazolidinecarboxylic acids and pharmaceutical compositions comprising such compounds |
| EP0214101A3 (de) | 1985-09-03 | 1989-05-31 | Ciba-Geigy Ag | Verwendung von Eisen(III)-Chelatoren vom Typ Desferrioxamin B und Desferriferrithiocin zur Behandlung von Malaria |
| EP0214933A3 (de) | 1985-09-03 | 1989-05-24 | Ciba-Geigy Ag | Kombinationspräparate zur Behandlung von Malaria |
| JPS62142168A (ja) | 1985-10-16 | 1987-06-25 | Mitsubishi Chem Ind Ltd | チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤 |
| DE3621540A1 (de) | 1986-06-27 | 1988-01-07 | Basf Ag | Chinolinderivate, verfahren zu ihrer herstellung, diese enthaltende mikrobizide und ihre verwendung zur bekaempfung von bakterien und pilzen |
| DE3735757A1 (de) | 1987-10-22 | 1989-05-03 | Degussa | Optisch aktive salze aus einem substituierten thiazolidin-4-carboxylat und 3-chlor-2-hydroxypropyltrimethylammonium, deren herstellung und verwendung |
| ES2047149T3 (es) | 1988-01-20 | 1994-02-16 | Ciba Geigy Ag | Procedimiento para la obtencion de compuestos complejos. |
| US5182402A (en) | 1988-11-07 | 1993-01-26 | Imperial Chemical Industries Plc | Herbicidal compositions |
| GB8826035D0 (en) | 1988-11-07 | 1988-12-14 | Ici Plc | Herbicidal compositions |
| US5106992A (en) | 1989-07-28 | 1992-04-21 | E. R. Squibb & Sons, Inc. | 3,5-dihydroxypentanoic acid derivatives useful as antihypercholesterolemic agents and method for preparing same |
| NL9001955A (nl) | 1990-09-05 | 1992-04-01 | Cedona Pharm Bv | Nieuwe thiazolidinederivaten. |
| US5393777A (en) | 1990-11-15 | 1995-02-28 | State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University | Deferration using anguibactin siderophore |
| KR100221041B1 (ko) | 1990-11-30 | 1999-09-15 | 야스이 쇼사꾸 | 2-아릴티아졸 유도체 및 그의 약제학적 조성물 |
| TW311136B (enExample) | 1990-11-30 | 1997-07-21 | Otsuka Pharma Co Ltd | |
| FR2677021B1 (fr) | 1991-05-31 | 1993-10-01 | Upsa Laboratoires | Nouveaux derives de thiazole antagonistes des recepteurs a l'angiotensine ii; leurs procedes de preparation, compositions pharmaceutiques les contenant. |
| AU5602594A (en) | 1992-11-16 | 1994-06-08 | University Of Florida Research Foundation, Inc. | 2-(pyrid-2'-yl)-2-thiazoline-4(s)-carboxylic acid derivatives |
| US5840739A (en) | 1992-11-16 | 1998-11-24 | University Of Florida Research Foundation, Inc. | Thiazoline acid derivatives |
| DE4301356A1 (de) | 1993-01-20 | 1994-07-21 | Basf Ag | Verfahren zur Herstellung von 2-Alkyl-4-fluormethyl-thiazolcarbonsäure-alkylestern |
| FR2749583B1 (fr) | 1996-06-07 | 1998-08-21 | Lipha | Nouveaux derives de thiazolidine -2,4- dione substitues, leurs procedes d'obtention et les compositions pharmaceutiques en renfermant |
| US20020049316A1 (en) | 1997-04-29 | 2002-04-25 | Halbert Stacie Marie | Protease inhibitors |
| MA26618A1 (fr) | 1998-04-09 | 2004-12-20 | Smithkline Beecham Corp | Composes et compositions pharmaceutiques pour le traitement du paludisme |
| US6147070A (en) | 1998-06-05 | 2000-11-14 | Facchini; Francesco | Methods and compositions for controlling iron stores to treat and cure disease states |
| US6083966A (en) | 1998-08-31 | 2000-07-04 | University Of Florida | Thiazoline acid derivatives |
| US6159983A (en) | 1998-09-18 | 2000-12-12 | University Of Florida | Method and composition for treatment of inflammatory bowel disease |
| NZ526880A (en) | 1998-09-21 | 2005-05-27 | Univ Florida | Antimalarial agents |
| US6251927B1 (en) | 1999-04-20 | 2001-06-26 | Medinox, Inc. | Methods for treatment of sickle cell anemia |
| DE19948434A1 (de) | 1999-10-08 | 2001-06-07 | Gruenenthal Gmbh | Substanzbibliothek enthaltend bicyclische Imidazo-5-amine und/oder bicyclische Imidazo-3-amine |
| US7160855B2 (en) | 2002-03-14 | 2007-01-09 | Children's Hospital & Research Center At Oakland | Enhancement of iron chelation therapy |
| WO2004017959A2 (en) | 2002-08-22 | 2004-03-04 | University Of Florida | Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin |
| US20040044220A1 (en) | 2002-08-22 | 2004-03-04 | University Of Florida | Antioxidant and radical scavenging activity of synthetic analogs of desferrithiocin |
| CA2538159A1 (en) | 2003-09-09 | 2005-03-17 | University Of Florida Research Foundation, Inc. | Polyamine-metal chelator conjugates |
| AU2003270473A1 (en) | 2003-09-09 | 2005-04-27 | University Of Florida | Desferrithiocin derivatives and their use as iron chelators |
| JP2008520669A (ja) | 2004-11-19 | 2008-06-19 | シバ バイオメディカル，エルエルシー | エリスロポエチン抵抗性を治療する方法 |
| BRPI0610644B8 (pt) | 2005-04-04 | 2021-05-25 | Univ Florida | composto e composição farmacêutica que compreende tal composto e um veículo ou diluente farmaceuticamente aceitável. |
| US20080194518A1 (en) | 2005-12-23 | 2008-08-14 | MOOKERJEE Pradip | Antimicrobial Compositions |
| CN101129381B (zh) | 2006-08-25 | 2012-02-01 | 天津和美生物技术有限公司 | 含β-内酰胺类抗生素和离子螯合剂的抗生素复方 |
| JP2010512398A (ja) | 2006-12-12 | 2010-04-22 | ユニバーシティ オブ フロリダ | デスフェリチオシン類縁体アクチニド除染剤 |
| US8324397B2 (en) * | 2007-03-15 | 2012-12-04 | University Of Florida Research Foundation, Inc. | Desferrithiocin polyether analogues |
| FR2922210A1 (fr) | 2007-10-11 | 2009-04-17 | Univ Louis Pasteur Etablisseme | Nouveaux composes, preparation et utilisations |
| MY163516A (en) * | 2008-07-14 | 2017-09-15 | Ferrokin Biosciences Inc | Novel salts and polymorphs of desazadesferrithiocin polyether analogues as metal chelation agents |
| BR112012001761A2 (pt) | 2009-07-27 | 2017-05-09 | Ferrokin Bioscience Inc | composto de formula i, composto farmacêutica e método de tratamento de uma condição mediada por metal em um indivduo |
| JP5925679B2 (ja) * | 2009-08-25 | 2016-05-25 | ユニバーシティ オブ フロリダ リサーチ ファウンデーション，インコーポレイティド | デスフェリチオシンポリエーテル類似体およびその使用 |
| US20130053387A1 (en) * | 2010-05-04 | 2013-02-28 | FerroKin BioScience, Inc. | Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents |
| WO2012027794A2 (en) | 2010-09-01 | 2012-03-08 | The Mental Health Research Institute Of Victoria | Method of treatment and agents useful for same |
| AU2012347595A1 (en) * | 2011-12-09 | 2014-06-26 | Ferrokin Biosciences, Inc. | Oral formulations for treating metal overload |
| WO2013090766A1 (en) * | 2011-12-16 | 2013-06-20 | University Of Florida Research Foundation, Inc. | Uses of 3'-desferrithiocin analogs |
| KR102111176B1 (ko) | 2011-12-16 | 2020-05-15 | 유니버시티 오브 플로리다 리서치 파운데이션, 인코포레이티드 | 4'-데스페리티오신 유사체의 용도 |
| WO2014134701A1 (en) | 2013-03-07 | 2014-09-12 | Kane Biotech Inc. | Antimicrobial-antibiofilm compositions and methods of use thereof |
-
2014
- 2014-11-21 JP JP2016533648A patent/JP6838966B2/ja not_active Expired - Fee Related
- 2014-11-21 CA CA2930966A patent/CA2930966A1/en not_active Abandoned
- 2014-11-21 US US15/038,188 patent/US10010535B2/en active Active
- 2014-11-21 EP EP14864521.1A patent/EP3071201A4/en not_active Withdrawn
- 2014-11-21 WO PCT/US2014/066965 patent/WO2015077655A1/en not_active Ceased
- 2014-11-21 AU AU2014352780A patent/AU2014352780A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017500295A5 (enExample) | ||
| CA2791738C (en) | Aryl imidazolyl compounds for the treatment of cancer | |
| JP2017502006A5 (enExample) | ||
| RU2019129727A (ru) | Применения пиримидопиримидинонов в качестве ингибиторов sik | |
| CA3105748A1 (en) | Pyridazine compounds for inhibiting nav1.8 | |
| JP2019094345A5 (enExample) | ||
| JP2017504595A5 (enExample) | ||
| JP2019504890A5 (enExample) | ||
| JP2020509022A5 (enExample) | ||
| JP2015531773A5 (enExample) | ||
| JP2019524883A5 (enExample) | ||
| JP2018522866A5 (enExample) | ||
| JP2021152063A5 (enExample) | ||
| JP2018515495A5 (enExample) | ||
| CA3002945A1 (en) | Methods of using c-met modulators | |
| JP2016074674A5 (enExample) | ||
| JP2013525495A (ja) | 金属キレート化剤としてのデスアザデスフェリチオシン類似体 | |
| JP2021046404A5 (enExample) | ||
| HRP20211782T1 (hr) | Derivati indola kao inhibitori replikacije denga virusa | |
| JP2019535723A5 (enExample) | ||
| JP2020516616A5 (enExample) | ||
| JP2023100842A (ja) | 置換フェニルスルホニルフェニルトリアゾールチオンおよびその使用法 | |
| JP2018515475A5 (enExample) | ||
| JP2007503432A5 (enExample) | ||
| JPWO2021133896A5 (enExample) |